We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Incretin Mimetic Can Cause Severe, Disabling Joint Pain, FDA Warns

(August 31, 2015, 2:10 PM EDT) -- SILVER SPRING, Md. — Incretin mimetic diabetes drug Januvia, Onglyza and Tradjenta can cause severe and disabling joint pain, the Food and Drug Administration warned Aug. 28.

In a drug safety communication, the FDA said it has added a new warning and precaution about the risk of joint pain to the labels of all prescription drugs in the class, also known as dipeptidyl peptidase-4 (DPP-4) inhibitors.

The drugs are prescribed to patients with type 2 diabetes to help lower blood sugar.

4 Brand Groups Affected...
To view the full article, register now.